Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2018 1
2020 1
2021 2
2022 1
2024 1
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean linaclotide plecanatide tenapanor ibs c (13 results)?
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. Chang L, et al. Gastroenterology. 2022 Jul;163(1):118-136. doi: 10.1053/j.gastro.2022.04.016. Gastroenterology. 2022. PMID: 35738724
The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conducted an evidence review of the following agents: tenapanor, plecanatide, linaclotide, tegaserod, lubiprostone, polyethyle …
The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conduct …
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database.
Andrews MB, Adler DG. Andrews MB, et al. Expert Opin Drug Saf. 2025 Jun 13:1-8. doi: 10.1080/14740338.2025.2519833. Online ahead of print. Expert Opin Drug Saf. 2025. PMID: 40503810
BACKGROUND: FDA approved treatments for constipation-predominant irritable bowel syndrome (IBS-C) include secretagogues (Linaclotide, Lubiprostone, and Plecanatide) and a retainagogue (Tenapanor). ...Tenapanor was most associated with dia …
BACKGROUND: FDA approved treatments for constipation-predominant irritable bowel syndrome (IBS-C) include secretagogues (Li …
Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Miner PB. Miner PB. Expert Rev Gastroenterol Hepatol. 2020 Feb;14(2):71-84. doi: 10.1080/17474124.2020.1722101. Epub 2020 Feb 5. Expert Rev Gastroenterol Hepatol. 2020. PMID: 31985305 Review.
Introduction: As an analogue of uroguanylin plecanatide binds to the Guanylate Cyclase-C receptor activating fluid and ion secretion in the small intestine with the same pH-dependent binding kinetics as the natural ligand. Plecanatide has been FDA approved as safe a …
Introduction: As an analogue of uroguanylin plecanatide binds to the Guanylate Cyclase-C receptor activating fluid and ion secretion …
New pharmacological treatment options for irritable bowel syndrome with constipation.
Nusrat S, Miner PB Jr. Nusrat S, et al. Expert Opin Emerg Drugs. 2015;20(4):625-36. doi: 10.1517/14728214.2015.1105215. Epub 2015 Nov 7. Expert Opin Emerg Drugs. 2015. PMID: 26548544 Review.
INTRODUCTION: Constipation predominant irritable bowel syndrome (IBS-C) is a common disorder and accounts for a large number of ambulatory visits. Sensory abnormalities, that is, presence of abdominal pain and discomfort, distinguish IBS-C from chronic …
INTRODUCTION: Constipation predominant irritable bowel syndrome (IBS-C) is a common disorder and accounts for a large number o …
[Pharmacologic Treatment of Irritable Bowel Syndrome with Predominant Constipation].
Kim DH, Song HY, Nam K; Korean Society of Neurogastroenterology and Motility. Kim DH, et al. Korean J Gastroenterol. 2025 Apr 25;85(2):110-116. doi: 10.4166/kjg.2025.002. Korean J Gastroenterol. 2025. PMID: 40276827 Free PMC article. Review. Korean.
Irritable bowel syndrome with predominant constipation (IBS-C) is a functional gastrointestinal disorder characterized by abdominal pain with chronic constipation and abdominal bloating, which could significantly impair the quality of life of patients and bring subs …
Irritable bowel syndrome with predominant constipation (IBS-C) is a functional gastrointestinal disorder characterized by abdo …
Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Black CJ, et al. Gastroenterology. 2018 Dec;155(6):1753-1763. doi: 10.1053/j.gastro.2018.08.021. Epub 2018 Aug 23. Gastroenterology. 2018. PMID: 30144426 Free article.
RESULTS: We identified 15 eligible randomized controlled trials of secretagogues that included 8462 patients. Linaclotide, lubiprostone, plecanatide, and tenapanor were superior to placebo for the treatment of IBS-C. ...Tenapanor (50 mg t …
RESULTS: We identified 15 eligible randomized controlled trials of secretagogues that included 8462 patients. Linaclotide, lubiprosto …
Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States.
Sendzischew Shane MA, Ruddy J, Cline M, Rosenbaum DP, Edelstein S, Moshiree B. Sendzischew Shane MA, et al. Clin Exp Gastroenterol. 2024 Aug 2;17:227-253. doi: 10.2147/CEG.S464375. eCollection 2024. Clin Exp Gastroenterol. 2024. PMID: 39114809 Free PMC article. Review.
A positive diagnostic strategy for IBS-C is recommended, based on clinical history, physical examination, and minimal laboratory tests. ...In patients with inadequate response to these therapies, 4 currently available therapies (lubiprostone, linaclotide, …
A positive diagnostic strategy for IBS-C is recommended, based on clinical history, physical examination, and minimal laborato …
Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.
Wechsler EV, Shah ED. Wechsler EV, et al. Drugs. 2021 Nov;81(17):1953-1968. doi: 10.1007/s40265-021-01634-7. Epub 2021 Nov 2. Drugs. 2021. PMID: 34727333 Review.
We performed a narrative review of the literature to summarize these important determinants of treatment choice including: labeled indications; clinical profiles of efficacy, safety, and tolerability of prescription drugs; and cost-effectiveness for diarrhea-predominant IBS drugs …
We performed a narrative review of the literature to summarize these important determinants of treatment choice including: labeled indicatio …
Review article: current and future treatment approaches for IBS with constipation.
Liu JJ, Brenner DM. Liu JJ, et al. Aliment Pharmacol Ther. 2021 Dec;54 Suppl 1:S53-S62. doi: 10.1111/apt.16607. Aliment Pharmacol Ther. 2021. PMID: 34927760 Review.
BACKGROUND: Multiple efficacious therapies are currently available for treating irritable bowel syndrome with constipation (IBS-C). IBS-C specific survey tools that assess symptom relief, treatment satisfaction, and quality of life are important for ga …
BACKGROUND: Multiple efficacious therapies are currently available for treating irritable bowel syndrome with constipation (IBS-C …
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH, Luthin DR. Thomas RH, et al. Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27. Pharmacotherapy. 2015. PMID: 26016701 Review.
Relatively small response rates, higher costs, and adverse effects associated with lubiprostone and linaclotide will likely render these agents suitable as second-line therapies in the treatment of IBS-C and CIC. Emerging potential treatment options include p …
Relatively small response rates, higher costs, and adverse effects associated with lubiprostone and linaclotide will likely render th …
12 results